The Breast Cancer Team led by Prof. Kefah Mokbel at The London Breast Institute of The Princess Grace Hospital have recently introduced a new gene test (BRCS Gene Testing) known as myRisk. The myRisk test evaluates 25 clinically actionable genes include the BRCA1 and BRCA2 genes and significantly improves our ability to identify people at higher risk for hereditary cancer, which may lead to prevention or early detection with the ability to reduce cancer incidence and mortality. Most of the genes in the panel are reflected in the National Comprehensive Cancer Network (NCCN) guidelines and the clinical relevance of all 25 genes is well characterized in the peer-reviewed medical literature. Additionally, all genes in the myRisk panel have a high to moderately-high penetrance and are associated with a significant increase in the lifetime risk of cancer for patients . Myriad myRisk Hereditary Cancer is a new diagnostic test (99.99% accuracy) that provides patients with information about their hereditary risk for eight major cancers including breast, colorectal, ovarian, endometrial, pancreatic, prostate, gastric cancers and melanoma. Prof. Kefah Mokbel believes that this new test that uses next generation sequencing (NGS) technology will soon replace standard BRCA analysis and will become the new platinum standard in genetic testing for cancer predisposition since most women test negative for the BRCA1 and BRCA2 genes.
If you are considering genetic testing for cancer risk in view of a personal or a family history of cancer, you can make an appointment with Prof. Kefah Mokbel’s team at The London Breast Institute: 0207 908 2040